Top Medical News
Novel lipoic acid choline ester eye drops safe, promising against presbyopia
7 hours ago
UNR844, an investigational topical lipoic acid choline ester eye drop, is safe and well-tolerated for the treatment of presbyopia and yields improvements in distance-corrected near visual acuity, a recent study has found.
Canagliflozin improves HF symptoms, QoL regardless of diabetes status
Pearl Toh, 10 hours ago
The SGLT2i* canagliflozin significantly improves symptoms and quality of life (QoL) early on during treatment in people with heart failure (HF) due to either reduced or preserved ejection fraction (rEF or pEF), regardless of whether they have type 2 diabetes (T2D), according to the CHIEF-HF** study presented at AHA 2021.
Cholecystectomy a risk factor for Parkinson’s disease in men
11 hours ago
Undergoing a surgery to remove the gallbladder appears to contribute to an increased risk of developing Parkinson’s disease (PD) in men, a study has found.
Caesarean delivery may reduce neonatal iron stores at birth
14 hours ago
Caesarean delivery appears to obstruct placental transfusion from mother to neonate and lessens iron stores at birth, a recent study suggests.
Diabetes-related foot ulceration hospitalization leads to lower hip, femoral BMD
16 hours ago
Hospitalization for diabetes-related foot ulcerations (DFU) seems to result in bilateral decreases in total hip and femoral bone mineral density (BMD), a recent study has found.
Vaginal panel assay helps vaginitis patients get accurate diagnosis
17 hours ago
An assay that detects DNA associated with bacterial vaginosis, vulvovaginal candidiasis, and Trichomonas vaginalis helps women get an accurate diagnosis, which in turn facilitates appropriate and timely treatment, according to a study.
Regular PPI use ups inflammatory bowel disease risk
19 hours ago
Regular use of proton pump inhibitors (PPI) seems to slightly aggravate the risk of inflammatory bowel disease, a recent study has found.
Special Reports
Product Highlight - Locoa
01 Dec 2021
Esflurbiprofen 40 mg transdermal patch
Product Highlight - Rinvoq
01 Dec 2021
Upadacitinib 15 mg XR-FC tab
01 Dec 2021
It has been estimated that diabetes – a chronic metabolic disorder resulting in hyperglycaemia – affects 422 million adults globally.1 In 2019, the disease caused 1.5 million deaths worldwide and the number of people with diabetes is expected to reach 642 million by 2040. 
Taking the big leapfrog to advance T2D care
01 Dec 2021
During the Guardians for Health Summit 2021 supported by Boehringer Ingelheim, several distinguished speakers shared their insights into the importance of type 2 diabetes (T2D) guideline adherence and patient empowerment, as well as the impact of clinical inertia on the burden of cardiorenal metabolic diseases.
Product Highlight - Evenity
01 Dec 2021
Romosozumab 105 mg/1.17 mL soln for inj
EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF
18 Nov 2021
Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.
NOACs in nonvalvular atrial fibrillation with multimorbidity: Where does apixaban stand?
02 Nov 2021
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice, affecting millions of people globally. Stroke is one of its devastating complications, with the risk steeply increasing with advancing age. Additionally, AF is associated with more than a tripling of the risk of systemic embolic (SE) events. [J Am Heart Assoc 2020;9:e016724]
Conference Reports
Non-overweight NAFLD patients have poor liver transplant outcomes
Roshini Claire Anthony, 03 Dec 2021

Non-overweight patients with non-alcoholic fatty liver disease (NAFLD) have an elevated risk of all-cause mortality following liver transplant and are also more likely to be removed from the liver transplant waitlist compared with obese/overweight patients, according to a study presented at The Liver Meeting Digital Experience™.

Inclisiran sustains LDL-C reduction in high-risk patients for ASCVD
Elaine Soliven, 03 Dec 2021
Treatment with inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) levels in patients with, or at high risk of, atherosclerotic cardiovascular disease (ASCVD), regardless of glycaemic status, based on a pooled analysis of the ORION-10* and ORION-11** studies presented at AHA 2021.
Milvexian prevents VTE after knee arthroplasty, bleeding risk low
Roshini Claire Anthony, 02 Dec 2021

Postoperative treatment with the oral factor XIa inhibitor milvexian could help prevent the incidence of venous thromboembolism (VTE) in patients undergoing elective knee arthroplasty, according to results of a phase II trial presented at AHA 2021.

Two-dose hep-B vaccine more seroprotective than three-dose regimen in chronic liver disease patients
Audrey Abella, 02 Dec 2021
In a pooled post hoc analysis of three phase III trials, a novel two-dose hepatitis B (hep-B) vaccine regimen trumped the traditional three-dose regimen in inducing seroprotection in patients with chronic liver disease (CLD).
Lefamulin scores again in multilobar pneumonia
Pearl Toh, 01 Dec 2021
The pleuromutilin inhibitor lefamulin shows similarly high efficacy as moxifloxacin (a standard fluoroquinolone therapy for clearing bacterial pneumonia) regardless of whether it was for unilobar or multilobar pneumonia, according to pooled data of the LEAP* 1 and 2 studies.
Higher sodium, lower potassium urine excretion tied to increased CV risk
Roshini Claire Anthony, 29 Nov 2021

Higher sodium and lower potassium intake, measured through repeat 24-hour urine samples, are tied to an elevated risk of cardiovascular (CV) events, according to a study presented at AHA 2021.

Add-on ezetimibe helps reduce LDL-C in post-ACS patients
Audrey Abella, 29 Nov 2021
The addition of ezetimibe to a statin led to reductions in low-density lipoprotein-cholesterol (LDL-C) in patients who have been stabilized after the presentation of an acute coronary syndrome (ACS), according to data presented at AHA 2021.